Q-omics provides the consensus-scored EBLN1 profile across patient tissues and cancer cell-line models. EBLN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EBLN1 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, EBLN1 RNA expression shows 9,203 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where EBLN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EBLN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EBLN1 survival associations across molecular data types. EBLN1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EBLN1 RNA expression–survival associations across cancer types. High EBLN1 expression shows unfavorable associations in ACC, KICH, UCEC, COAD and BLCA, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EBLN1 RNA expression.
This table summarizes EBLN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EBLN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EBLN1 shows lower tumor expression in KICH and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher EBLN1 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p < 0.001).
This table shows molecular features associated with EBLN1 in patient tissues and cancer cell lines. In patient samples, EBLN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EBLN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
